Bristol Myers Squibb (CGT Mfg) vs Minaris Advanced Therapies: CDMO Comparison

How does Bristol Myers Squibb (CGT Mfg) compare to Minaris Advanced Therapies?

As of Aug 2026, Bristol Myers Squibb (CGT Mfg): 8 FDA inspections (including 4 NAI, 4 VAI and 0 OAI), 2 EMA/MHRA GMP certificates. Signal Score 87. Minaris Advanced Therapies: 3 FDA inspections (including 2 NAI, 1 VAI and 0 OAI), 2 EMA/MHRA GMP certificates. Signal Score 83.1. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Bristol Myers Squibb (CGT Mfg) and Minaris Advanced Therapies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Bothell, WA · Warren, NJ
Signal Score
87/100
Quality (FDA + GMP)
97/100
FDA inspections
8
— NAI / VAI / OAI
4 / 4 / 0
FDA warning letters
0
EMA GMP certificates (active)
1
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
586
Capacity
—
Modalities
CAR-T, Cell Therapy
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score
83/100
Quality (FDA + GMP)
99/100
FDA inspections
3
— NAI / VAI / OAI
2 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
2
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Limited
Modalities
CAR-T, Cell Therapy

Key differences

  • Bristol Myers Squibb (CGT Mfg) has more FDA inspections on record (8 vs 3) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Bristol Myers Squibb (CGT Mfg) maintains 1 MHRA / UK GMP certificate; Minaris Advanced Therapies does not.
  • Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (586 vs 0) — a broader sponsor book.

Across the cross-modality scorecard, Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Bristol Myers Squibb (CGT Mfg) vs Minaris Advanced Therapies

How does Bristol Myers Squibb (CGT Mfg) compare to Minaris Advanced Therapies?

On CDMO Signal's composite Signal Score, Bristol Myers Squibb (CGT Mfg) is 87/100 and Minaris Advanced Therapies is 83/100; Bristol Myers Squibb (CGT Mfg) has 8 FDA inspections on record vs 3 for Minaris Advanced Therapies; European coverage is 2 active EMA+MHRA certificates for Bristol Myers Squibb (CGT Mfg) vs 2 for Minaris Advanced Therapies. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Bristol Myers Squibb (CGT Mfg) or Minaris Advanced Therapies?

Both Bristol Myers Squibb (CGT Mfg) and Minaris Advanced Therapies maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Bristol Myers Squibb (CGT Mfg) has 8 FDA inspections on record; Minaris Advanced Therapies has 3.

How do Bristol Myers Squibb (CGT Mfg) and Minaris Advanced Therapies compare on European GMP coverage?

Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. Minaris Advanced Therapies holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Bristol Myers Squibb (CGT Mfg) or Minaris Advanced Therapies?

Bristol Myers Squibb (CGT Mfg) is matched to 586 ClinicalTrials.gov records as a manufacturing partner; Minaris Advanced Therapies is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

What does the Signal Score gap mean in practice?

Bristol Myers Squibb (CGT Mfg) carries a Signal Score of 87/100 and Minaris Advanced Therapies carries 83/100 — essentially tied for Bristol Myers Squibb (CGT Mfg). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Bristol Myers Squibb (CGT Mfg) and Minaris Advanced Therapies for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.